BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS

Main measures

• - The primary endpoint is the mean four-week rate of occurrence of new Gd-enhancing lesions on the cranial MRIs performed every 4 weeks from Week 28 through Week 48 (6 MRIs).

  MRI lesions

1. Oct 2026In scope changed from true to false

1. Started

   Jul 2005